Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

Abstract Background The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were explored to improve antischistosomal...

Full description

Bibliographic Details
Main Authors: Maha M. Eissa, Mervat Z. El-Azzouni, Labiba K. El-Khordagui, Amany Abdel Bary, Riham M. El-Moslemany, Sara A. Abdel Salam
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Parasites & Vectors
Subjects:
Praziquantel
Miltefosine
Lipid Nanocapsules
Schistosoma mansoni
Nanocombination
Multistage activity
Online Access:http://link.springer.com/article/10.1186/s13071-020-04346-1

Internet

http://link.springer.com/article/10.1186/s13071-020-04346-1

Similar Items